Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3–5: An Analysis of a Randomized Trial (RESCUE)

医学 内科学 阶段(地层学) 抢救疗法 随机对照试验 血红蛋白 重症监护医学 生物 古生物学
作者
Pablo E. Pérgola,Michael H. Davidson,Camilla Jensen,Amir Abbas Mohseni Zonoozi,Dominic S. Raj,Philip Andreas Schytz,Katherine R. Tuttle,Vlado Perkovic
出处
期刊:Journal of The American Society of Nephrology [American Society of Nephrology]
卷期号:35 (1): 74-84 被引量:14
标识
DOI:10.1681/asn.0000000000000245
摘要

Significance Statement Systemic inflammation in CKD can lead to anemia. Ziltivekimab, a fully human monoclonal antibody targeting the IL-6 ligand, has been shown to reduce systemic inflammation in patients with CKD. It has also been shown to increase serum albumin in patients on hemodialysis with inflammation and hyporesponsiveness to treatment with erythropoiesis-stimulating agents. This exploratory analysis of the RESCUE clinical trial found that among patients with CKD stage 3–5 and systemic inflammation, ziltivekimab treatment significantly increased hemoglobin (Hb) levels after 12 weeks compared with placebo. Ziltivekimab was also associated with significant increases in serum iron levels, total iron-binding capacity, and transferrin saturation. No major safety concerns were reported. Further clinical trials are warranted to study ziltivekimab's potential for anemia management in patients with CKD. Background In the phase 2 RESCUE clinical trial, ziltivekimab, a fully human monoclonal antibody against the IL-6 ligand, significantly reduced the biomarkers of inflammation compared with placebo, in patients with CKD and systemic inflammation (high-sensitivity C-reactive protein ≥2 mg/L). The aim of this subanalysis of RESCUE trial data was to assess the effect of ziltivekimab on Hb and iron homeostasis in this patient population. Methods This was an analysis of exploratory end points from the RESCUE trial (NCT03926117), which included 264 adults with CKD stage 3–5 and high-sensitivity C-reactive protein ≥2 mg/L. Participants received placebo or subcutaneous ziltivekimab (7.5, 15, or 30 mg) (1:1:1:1) once every 4 weeks, up to 24 weeks. End points for this analysis were changes in Hb and biomarkers of iron homeostasis from baseline to week 12. Results The trial was terminated early due to the coronavirus disease 2019 pandemic, and thus, data up to week 12 are presented. Hb levels significantly increased from baseline to week 12 with ziltivekimab 7.5, 15, and 30 mg (treatment differences versus placebo: +0.57 g/dl [95% confidence interval, 0.27 to 0.86], +1.05 g/dl [0.76 to 1.33], and +0.99 g/dl [0.70 to 1.28], respectively, all P < 0.001). Ziltivekimab was associated with significant increases in serum iron levels, total iron-binding capacity, and transferrin saturation from baseline to week 12 ( P < 0.05 versus placebo for all doses and comparisons). Cases of sustained thrombocytopenia, sustained neutropenia, anemia, and iron deficiency anemia were infrequent and similar across all groups. Conclusions Anti-inflammatory therapy with ziltivekimab improved the markers of anemia and iron homeostasis in people with stage 3–5 CKD and systemic inflammation, suggesting a possible role in anemia management.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
我是老大的应助被橘色的嘟嘟采纳,获得10
刚刚
Ai发布了新的文献求助10
1秒前
面包糠完成签到,获得积分10
2秒前
KYT2025发布了新的文献求助10
3秒前
xing_xing的应助被霍则风采纳,获得60
3秒前
3秒前
耍酷爆米花完成签到,获得积分10
3秒前
lkh发布了新的文献求助10
3秒前
3秒前
xing_xing的应助被霍则风采纳,获得20
4秒前
榴莲完成签到,获得积分10
4秒前
俏皮的又夏完成签到 ,获得积分10
4秒前
4秒前
小朱雀发布了新的文献求助10
5秒前
5秒前
5秒前
阿申爱乐的应助被lin采纳,获得30
6秒前
6秒前
cccc完成签到,获得积分10
6秒前
7秒前
桐桐的应助被77采纳,获得10
7秒前
8秒前
8秒前
Jerry发布了新的文献求助10
9秒前
完美世界的应助被新新新采纳,获得10
9秒前
传奇3的应助被Garnieta采纳,获得10
9秒前
Nole的应助被Garnieta采纳,获得10
10秒前
10秒前
cyx给cyx的求助进行了留言
10秒前
情怀的应助被Garnieta采纳,获得10
10秒前
王晨发布了新的文献求助10
10秒前
KYT2025完成签到,获得积分10
11秒前
LINLIN完成签到,获得积分10
11秒前
li发布了新的文献求助10
11秒前
12秒前
12秒前
van发布了新的文献求助10
12秒前
Vgod发布了新的文献求助20
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188118
求助须知:如何正确求助?哪些是违规求助? 9575977
关于积分的说明 21844428
捐赠科研通 7785918
什么是DOI,文献DOI怎么找? 3435205
关于科研通互助平台的介绍 2559558
邀请新用户注册赠送积分活动 2482065